Table 1.
Demographic profile
| Number of patients (n) | 1,406 |
| Age (years) | 62.14 (39–84) |
| Prostate-specific antigen (n) | 8.53 (0.22–82.00) |
| Clinical stage (n) | |
| T1 | 13 (0.95%) |
| T1a | 2 (0.1%) |
| T1b | 2 (0.1%) |
| T1c | 335 (24.2%) |
| T2 | 57 (4.1%) |
| T2a | 317 (22.9%) |
| T2b | 173 (12.5%) |
| T2c | 385 (27.8%) |
| T3 | 30 (2.2%) |
| T3a | 68 (4.9%) |
| T3b | 2 (0.1%) |
| T3c | 1 (0.1%) |
| 4 | 1 (0.1%) |
| Gleason score (n) | |
| 6 | 466 (33.4%) |
| 7 | 836 (59.9%) |
| 8 | 80 (5.7%) |
| 9 | 13 (0.9%) |
| 10 | 1 (0.1%) |
| D’Amico classification | |
| Low | 261 (18.6%) |
| Intermediate | 931 (66.2%) |
| High | 214 (15.2%) |
| Intra- and postoperative | |
| Operation duration (min) | 198.08 (60–522) |
| Console time (min) | 161.05 (10–450) |
| Mean estimated blood loss (ml) | |
| ≤49ml | 152 (11.5%) |
| 50–99ml | 51 (3.9%) |
| 100–199ml | 364 (27.6%) |
| 200–499ml | 292 (22.1%) |
| ≥500ml | 460 (34.9%) |
| Blood transfusion (n) | 10 (0.7%) |
| Complications (Clavien) (n) | |
| 1 | 50 (4.4%) |
| 2 | 23 (2.0%) |
| 3a | 13 (1.1%) |
| 3b | 35 (3.1%) |
| 4a | 2 (0.2%) |
| 4b | 4 (0.4%) |
| Positive surgical margin (n) | 289 (20.7%) |
| Catheter time (days) | 10.95 (0–14) |
| Pathological features | |
| Pathological stage (n) | |
| pT0 | 3 (0.2%) |
| pT1a | 1 (0.1%) |
| pT1b | 0 (0.0%) |
| pT1c | 7 (0.5%) |
| pT2 | 14 (1.0%) |
| pT2+ | 54 (3.9%) |
| pT2a | 97 (6.9%) |
| pT2b | 28 (2.0%) |
| pT2c | 840 (60.2%) |
| pT3a | 274 (19.6%) |
| pT3b | 75 (5.4%) |
| pT4 | 2 (0.1%) |
| pT4a | 1 (0.1%) |
| Gleason score (n) | |
| 6 | 298 (21.4%) |
| 7 | 967 (69.5%) |
| 8 | 102 (7.3%) |
| 9 | 22 (1.6%) |
| 10 | 2 (0.1%) |